Skip to main content
SpringerLink
Log in

Elevated serum ca15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Background

The clinical usefulness of circulating tumor markers in breast cancer as recurrence indicators during follow-up or monitoring treatment response is still an open question. There are some patients with normal tumor marker levels who have apparent recurrence foci. In this study, we evaluated the relationships between CEA or CA15-3 levels and clinicopathological factors or outcome in patients who had died from recurrent breast cancer.

Methods

Two hundred-twenty deceased patients who had had recurrent or advanced breast cancer and who had been treated between 1986 and 2000 were enrolled in a retrospective study. Serum CEA and CA15-3 were measured regularly during the clinical course until death.

Results

The rates of CEA and CA15-3 positivity were 41.4% and 50.9% at the time of recurrence, and rose to 67.3% and 76.8% after recurrence, respectively. The CA15-3 and CEA positivity rates significantly correlated with ER and PgR status. Serum CA15-3 status correlated significantly with survival after recurrence. Patients with CA15-3 negativity had poorer prognoses than CA15-3 positive patients. Multivariate analysis revealed that CA15-3 status was one of the significant factors for survival after recurrence.

Conclusions

Tumor markers, especially CA15-3, might reflect the biological characteristics of tumors such as ER or PgR status, and may be useful prognostic predictors in recurrent breast cancer. Elevated CA15-3 levels correlated with positive estrogen receptor and favorable outcome in deceased patients with recurrent breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

CEA:

Carcinoembryonic antigen

CR:

Complete response

PR:

Partial response

NC:

No change

PD:

Progressive disease

References

  1. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.J Natl Cancer Inst 88:1456–1466, 1996.

    Article  PubMed  CAS  Google Scholar 

  2. Hayes DF: Determination of clinical utility of tumor markers: a tumor marker utility grading system.Recent Results Cancer Res 152:71–85, 1998.

    PubMed  CAS  Google Scholar 

  3. Stearns V, Yamauchi H, Hayes DF: Circulating tumor markers in breast cancer: accepted utilities and novel prospects.Breast Cancer Res Treat 52:239–259, 1998.

    Article  PubMed  CAS  Google Scholar 

  4. Cheung KL, Evans AJ, Robertson JF: The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy.Breast Cancer Res Treat 67:273–278, 2001.

    Article  PubMed  CAS  Google Scholar 

  5. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, D’Alessandro R, Carone MD, Cicchetti A, Ricciotti A, Venture I, Perri P, Di Filippo F, Cognetti F, Botti C, Roselli M: A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.Clin Cancer Res 7:2357–2362, 2001.

    PubMed  CAS  Google Scholar 

  6. Gion M, Peloso L, Mione R, Vignati G, Fortunate A, Saracchini S, Biasioli R, Gulisano M, Cappelli G: Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.Cancer J 7:181–190, 2001.

    PubMed  CAS  Google Scholar 

  7. Jager W, Eibner K, Loffler B, Gleixner S, Kramer S: Serial CEA and CA15-3 measurements during follow-up of breast cancer patients.Anticancer Res 20:5179–5182, 2000.

    PubMed  CAS  Google Scholar 

  8. Gion M, Mione R, Leon AE, Luftner D, Molina R, Possinger K, Robertson JF: CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases.Eur J Cancer 37:355–363, 2001.

    Article  PubMed  CAS  Google Scholar 

  9. Lumachi F, Brandes AA, Ermani M, Bruno G, Boccagni P: Sensitivity of serum tumor markers CEA and CA15-3 in breast cancer recurrences and correlation with different prognostic factors.Anticancer Res 20:4751–4755, 2000.

    PubMed  CAS  Google Scholar 

  10. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR; American Society of Clinical Oncology Tumor Markers Expert Panel: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.J Clin Oncol 19:1865–1878, 2001.

    PubMed  Google Scholar 

  11. Canizares F, Sola J, Perez M, Tovar I, De Las Heras M, Salinas J, Penafiel R, Martinez P: Preoperative values of CA15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis.Tumour Biol 22:273–281, 2001.

    Article  PubMed  CAS  Google Scholar 

  12. McLaughlin R, McGrath J, Grimes H, Given HF: The prognostic value of the tumor marker CA 15-3 at initial diagnosis of patients with breast cancer.Int J Biol Markers 15:340–342, 2000.

    PubMed  CAS  Google Scholar 

  13. Duffy MJ, Shering S, Sherry F, McDermott E, O’Higgins N: CA15-3: a prognostic marker in breast cancer.Int J Biol Markers 15:330–333, 2000.

    PubMed  CAS  Google Scholar 

  14. Ebeling FC, Schmitt UM, Untch M, Nagel D, Fateh-Moghadam A, Stieber P, Seidel D: Tumour markers CEA and CA15-3 as Prognostic factors in breast cancer-univariate and multivariate analysis.Anticancer Res 19:2545–2550, 1999.

    PubMed  CAS  Google Scholar 

  15. Shering SG, Sherry F, McDermott EW, O’Higgins NJ, Duffy MJ: Preoperative CA15-3 concentrations predict outcome of patients with breast carcinoma.Cancer 83:2521–2527, 1998.

    Article  PubMed  CAS  Google Scholar 

  16. Lauro S, Trasatti L, Bordin F, Lanzetta G, Bria E, Gelibter A, Reale MG, Vecchione A: Comparison of CEA, MCA, CA15-3 and CA27-29 in follow-up and monitoring therapeutic response in breast cancer patients.Anticancer Res 19:3511–3515, 1999.

    PubMed  CAS  Google Scholar 

  17. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, Farrus B, Latre ML, Escriche C, Estape J, Ballesta AM: c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.Breast Cancer Res Treat 51:109–119, 1998.

    Article  PubMed  CAS  Google Scholar 

  18. Saiki T, Nagao K, Nishimura R, Matsuda M, Baba K, Matsuoka Y, Yamashita H, Fukuda M, Higuchi A, Suzuki S: Clinical significance of tumor marker in recurrent breast cancer -a comparison of tumor marker positive cases and negative cases.Jpn J Breast Cancer 9:639–644, 1994 (in Japanese with English abstract).

    Google Scholar 

  19. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC: The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature.Cancer 91:1973–1982, 2001.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Kumamoto City Hospital, Japan

    Reiki Nishimura, Kazuharu Nagao, Masakazu Matsuda, Ken-ichirou Baba, Yukio Matsuoka & Hiroya Yamashita

  2. Clinical Pathology, Kumamoto City Hospital, Japan

    Haruhiko Miyayama

Authors
  1. Reiki Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuharu Nagao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haruhiko Miyayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masakazu Matsuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ken-ichirou Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yukio Matsuoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroya Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Reiki Nishimura.

Additional information

Reprint requests to Reiki Nishimura, Department of Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, Kumamoto City, Kumamoto 862-8505, Japan.

About this article

Cite this article

Nishimura, R., Nagao, K., Miyayama, H. et al. Elevated serum ca15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer. Breast Cancer 10, 220–227 (2003). https://doi.org/10.1007/BF02966721

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02966721

Key words

Search

Navigation